- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Sa | Regulatory tracker: Ahead of FDA verdicts, EU clears AbbVie's Rinvoq in alopecia, vitiligo | ||
| 31.07. | Amylyx demystifies post-bariatric hypoglycemia with patient education website | ||
| 31.07. | Daiichi Sankyo flags accounting error, as shares tank despite revenue beat | ||
| 31.07. | AbbVie's Skyrizi shrugs off new competition as it thrives in growing psoriasis market | ||
| 31.07. | Xpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis | ||
| 30.07. | Pfizer takes Litfulo to regulators in vitiligo challenge to Incyte, AbbVie | ||
| 30.07. | YouTuber MrBeast welcomes Amgen to the channel, kicking off pediatric cancer funding effort | ||
| 30.07. | Alnylam shares tank 29% as Amvuttra disappoints with ATTR outlook cut for 2026 | ||
| 30.07. | Booming Dupixent sales fuel Regeneron's biggest quarter since pandemic | ||
| 30.07. | New CEO Garijo sketches out vision to reverse Sanofi's fortunes as Q2 delivers impressive sales beat | ||
| 30.07. | Bristol Myers delays Cobenfy Alzheimer's psychosis readout again amid another quarterly beat | ||
| 30.07. | RFK Jr.'s Gardasil litigation ties subject to fresh lawmaker scrutiny after Merck settlement | ||
| 30.07. | Viatris runs into FDA roadblock after advertising on-the-go use of cystic fibrosis inhaler | ||
| 29.07. | Biogen flips '26 guidance from expected decline to sales increase | ||
| 29.07. | Boosted by CMS settlement, Incyte expects Opzelura to cross $1B in 2026 | ||
| 29.07. | Teva's innovation engine offsets generics slump, leaving one analyst 'shocked' by Ajovy's surge | ||
| 29.07. | PMCPA sanctions melatonin drugmaker over misleading information | ||
| 28.07. | How 2 FDA citations complicate Hengrui, Elevar's push for liver cancer combo approval | ||
| 28.07. | With $5.5B settlement offer, J&J could be on its way to resolving talc litigation | ||
| 28.07. | Baxter issues recall of antibiotic IV bags after bits of cardboard flagged in solution | ||
| 28.07. | GSK CEO targets $2.5B in cost savings from mature products, procurement, supply chain | ||
| 28.07. | Havas Lynx revamps New York C-suite 16 months after last shakeup | ||
| 27.07. | FDA approves Otsuka's ADHD drug Simtriyo, teeing up its 'next major CNS launch' | ||
| 27.07. | On 4th try, Outlook Therapeutics scores FDA nod for reformulated version of Roche's Avastin for AMD | ||
| 27.07. | Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chapter |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.